Kiniksa 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12345678»
  • ||||||||||  Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa
    Review, Journal:  Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease. (Pubmed Central) -  Oct 3, 2021   
    NLRP3 inflammasome, a macromolecular structure sensing damage and releasing pro-inflammatory cytokines, is centrally involved as it releases interleukin (IL)-1β, whose auto-induction feeds an autoinflammatory disease, mostly responsible for recurrences. Colchicine, an inhibitor of NLRP3 inflammasome formation, and IL-1-targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    [VIRTUAL] Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease () -  Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1836;    
    Timely recognition of DRESS reactions and withdrawal of all IL-1 and IL-6 inhibitors improve outcomes in Stills disease, lessens risk of the often fatal drug-associated lung disease and may allow resolution of DLD. Mechanisms underlying cross reactions between these structurally different drugs are not known.
  • ||||||||||  mavrilimumab (KPL-301) / Kiniksa, Actemra IV (tocilizumab) / Roche, JW Pharma
    [VIRTUAL] Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab () -  Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1678;    
    The frequency and magnitude of CRP and ESR elevations at relapse were similar in both treatment groups, indicating that CRP and ESR retain their clinical value under GM-CSF blockade therapy. Transient CRP and ESR elevation without relapse, indicating possible subclinical activity, occurred more often in PBO recipients.
  • ||||||||||  Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
    Preclinical, Review, Journal:  Promise of the NLRP3 Inflammasome Inhibitors in In Vivo Disease Models. (Pubmed Central) -  Sep 5, 2021   
    For instance, treatments that focus on systemically negating IL-1β (i.e., anakinra, rilonacept, and canakinumab) have been reported to result in an escalated peril of infections. Therefore, given the therapeutic promise of an NLRP3 inhibitor, the concerted escalated venture of the scientific sorority in the advancement of small molecules focusing on direct NLRP3 inflammasome inhibition is quite predictable.
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Journal:  The IL-1 trap rilonacept resolves and prevents recurrent pericarditis. (Pubmed Central) -  Sep 2, 2021   
    Therefore, given the therapeutic promise of an NLRP3 inhibitor, the concerted escalated venture of the scientific sorority in the advancement of small molecules focusing on direct NLRP3 inflammasome inhibition is quite predictable. No abstract available
  • ||||||||||  mavrilimumab (KPL-301) / Kiniksa
    Review, Journal:  Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review. (Pubmed Central) -  Aug 20, 2021   
    Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVID-19 patients, specifically those patients with pneumonia. With this review paper, we aim to demonstrate the inhibitory effect of mavrilimumab on cytokine storms in patients with COVID-19 by reviewing published clinical trials and emphasize the importance of extensive future trials.
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Journal:  New Indication for Rilonacept. (Pubmed Central) -  Aug 11, 2021   
    Rilonacept (Araclyst) has been approved to treat recurrent pericarditis and to reduce the risk of recurrence in adults and children 12 years of age and older. The drug is given subcutaneously.
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Review, Journal:  Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments. (Pubmed Central) -  Aug 5, 2021   
    Recent studies added evidence to the importance of anti-IL-1 drugs in the treatment of recurrent pericarditis with raised C-reactive protein. In the era of tailored medicine, anti-IL-1 agents may be very useful in the subset of patients with recurrent pericarditis and a clear inflammatory phenotype.
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    [VIRTUAL] Anti-interleukin 1 agents for the treatment of recurrent pericarditis. () -  Jul 6, 2021 - Abstract #ESC2021ESC_4478;    
    After discontinuing rilonacept during RW, HRQoL scores worsened at recurrence and improved upon receipt of bail-out rilonacept, similar to pain. In patients with RP, anti-IL-1 agents (anakinra and rilonacept) are efficacious for prevention of recurrences, without severe adverse events.
  • ||||||||||  mavrilimumab (KPL-301) / Kiniksa
    Trial completion, Trial primary completion date:  KPL-301 for Subjects With Giant Cell Arteritis (clinicaltrials.gov) -  Jul 2, 2021   
    P2,  N=70, Completed, 
    In patients with RP, anti-IL-1 agents (anakinra and rilonacept) are efficacious for prevention of recurrences, without severe adverse events. Active, not recruiting --> Completed | Trial primary completion date: Dec 2020 --> Aug 2020
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Journal:  Pericarditis (Pubmed Central) -  Jul 1, 2021   
    Other IL-1 receptor antagonists have shown promising results (canakinumab, rilonacept). Further evaluation in larger prospective clinical trials is needed to confirm the long-term efficacy and safety of anti-IL1."
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Review, Journal:  Acute recurrent pericarditis: from pathophysiology towards new treatment strategy. (Pubmed Central) -  Jun 30, 2021   
    Other IL-1 receptor antagonists showed promising results (canakinumab, rilonacept). However, IL-1 receptor antagonists' position in the treatment algorithm of recurrent pericarditis needs further evaluation in larger prospective clinical trials to replicate initial findings as well as to assess safety, cost-effectiveness and long-term efficacy.
  • ||||||||||  Ilaris (canakinumab) / Novartis
    Clinical, Journal:  Canakinumab for the treatment of adult-onset Still's disease. (Pubmed Central) -  Jun 24, 2021   
    The choice of treatment is a relevant issue for patients and the national health services. The available data for canakinumab indicate that this drug in AOSD patients is effective and well tolerated.
  • ||||||||||  Stelara (ustekinumab) / J&J, mavrilimumab (KPL-301) / Kiniksa, Actemra IV (tocilizumab) / Roche, JW Pharma
    Preclinical, Journal:  Giant cell arteritis: what is new in the preclinical and early clinical development pipeline? (Pubmed Central) -  Jun 10, 2021   
    However, much remains to be learned about its optimal usage in GCA and a substantial minority of patients do not achieve sustained glucocorticoid-free remission with tocilizumab. Numerous exciting new agents are under investigation to fill this treatment gap in GCA, with the GM-CSF inhibitor mavrilimumab, and IL-12/23 blockade with ustekinumab providing promise through targeting the GCA pathogenic pathway in its proximal portion.
  • ||||||||||  Journal:  Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. (Pubmed Central) -  May 22, 2021   
    Lymphocyte‑targeting agents include rituximab and belimumab, which act against B cells by different mechanisms, and abatacept, which is a T cell costimulation modulator...Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, and upadacitinib) and phosphodiesterase 4 inhibitors (apremilast) form this group...During pregnancy limited data exits, but anti-TNFα, rituximab, and anakinra seem to be safe. Biologic agents are expensive, but biosimilars have raised as a more cost-effective option and an opportunity to treat a greater number of patients.
  • ||||||||||  mavrilimumab (KPL-301) / Kiniksa, Actemra IV (tocilizumab) / Roche, JW Pharma
    [VIRTUAL] UTILITY OF CRP AND ESR IN THE DIAGNOSIS OF GIANT CELL ARTERITIS RELAPSE IN A PHASE 2 TRIAL OF MAVRILIMUMAB () -  May 21, 2021 - Abstract #EULAR2021EULAR_2828;    
    The frequency and magnitude of CRP and ESR elevations at relapse were similar in both treatment groups, suggesting that CRP and ESR remain useful in assessments of disease activity in mavrilimumab-treated patients. CRP and ESR elevations without GCA-related signs/symptoms occurred more often in placebo recipients.